Moreover, overexpression of cellular MET (c-MET)/MET has been documented in diverse malignancies, including NSCLC, hepatocellular carcinoma, gastroesophageal cancer, and gliomas, further emphasizing their role in oncogenesis [29, 35–37]. This evidence concerns the gene MET and hepatocellular carcinoma.